Review paper<br>Ghrelin antagonists in type 2 diabetes mellitus therapy – is it a safe path?

Waldemar Olszewski; Jerzy Głuszek

eISSN: 2084-9877
ISSN: 1896-9666

Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review

Current issue Archive About the journal Contact Instructions for authors

2/2010
vol. 5

Send email

Copy url:

abstract:

Review paper
Ghrelin antagonists in type 2 diabetes mellitus therapy – is it a safe path?

Waldemar Olszewski

,

Jerzy Głuszek

Przegląd Kardiodiabetologiczny 2010; 5 (2): 98–105

Online publish date: 2010/11/04

View full text Get citation

As we are facing pandemia of type 2 diabetes mellitus new methods of treatment are searched. In patients with type 2 diabetes mellitus serum ghrelin levels are decreased. Ghrelin is a substance with multidimensional influence, that takes part in central and peripheral metabolism regulation, stimulates pituitary gland hormones release and increases cardiac output and decreases peripheral vascular resistance. Ghrelin also regulates gastric emptying and memory processes. Regarding ghrelin’s wide biologic functions, the use of ghrelin antagonists only in the matter of metabolism seems to be difficult to achieve and unpredictable. Researches on ghrelin antagonists as new drugs in type 2 diabetes mellitus are presently running.

keywords:

Review paperGhrelin antagonists in type 2 diabetes mellitus therapy – is it a safe path?

Waldemar Olszewski , Jerzy Głuszek

ghrelin, ghrelin antagonists, diabetes mellitus (type 2), obesity

Review paper
Ghrelin antagonists in type 2 diabetes mellitus therapy – is it a safe path?

Waldemar Olszewski

,

Jerzy Głuszek